Unicycive Therapeutics, Inc. (UNCY)
NASDAQ: UNCY · Real-Time Price · USD
3.970
+0.010 (0.25%)
Sep 23, 2025, 3:15 PM EDT - Market open
Unicycive Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts that cover Unicycive Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $55.2, which forecasts a 1,290.43% increase in the stock price over the next year. The lowest target is $21 and the highest is $90.
Price Target: $55.2 (+1,290.43%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Unicycive Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 4 | 4 | 4 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Benchmark | Benchmark | Buy Maintains $3 → $21 | Buy | Maintains | $3 → $21 | +428.97% | Sep 15, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $90 | Strong Buy | Initiates | $90 | +2,167.00% | May 27, 2025 |
| Guggenheim | Guggenheim | Strong Buy Initiates $60 | Strong Buy | Initiates | $60 | +1,411.34% | Apr 21, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +1,789.17% | Apr 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $40 → $75 | Strong Buy | Maintains | $40 → $75 | +1,789.17% | Apr 1, 2025 |
Financial Forecast
Revenue This Year
5.31M
Revenue Next Year
243.35M
from 5.31M
Increased by 4,481.14%
EPS This Year
-2.59
from -5.65
EPS Next Year
6.28
from -2.59
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 26.6M | 522.5M | |||
| Avg | 5.3M | 243.4M | |||
| Low | n/a | 39.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 9,736.8% | |||
| Avg | - | 4,481.1% | |||
| Low | - | 637.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.22 | 15.44 | |||
| Avg | -2.59 | 6.28 | |||
| Low | -3.04 | -1.31 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.